



****Important Update ****

**Clozapine Risk Evaluation and Mitigation Strategy (REMS)
Certain Program Requirements Temporarily Suspended**

Providers and pharmacies were [required](#) to re-certify and re-enroll patients in the clozapine REMS program by November 15, 2021 to continue to prescribe or dispense clozapine. Due to problems with implementation and in response to provider and pharmacy concerns, [the FDA has temporarily suspended certain REMS program requirements](#) to ensure continuity of care for patients taking clozapine. Until further notice:

- **Pharmacists** may dispense clozapine without a REMS dispense authorization (RDA).
- **Wholesalers** may continue to ship clozapine to pharmacies and health care settings without confirming enrollment in the REMS.

Abrupt discontinuation of clozapine can result in significant complications for patient treatment. Health care professionals should use their clinical judgment with regard to prescribing and dispensing clozapine to patients with an absolute neutrophil count (ANC) within the acceptable range.

Prescribers and pharmacists should continue to [re-certify and re-enroll their patients in the Clozapine REMS](#).